Exclusive: 90% of China’s Synovac employees, families take coronovirus vaccine, CEO says

BEIJING (Reuters) – Nearly 90% of Synovac Biotech Limited employees and their families have taken an experimental coronavirus vaccine developed by the Chinese firm under the country’s emergency use program, its chief executive said on Sunday.

Following the outbreak of COVID-19 in Beijing, China on September 5, 2020, a sign of Synovac Biotech Limited is seen at the 2020 China International Fair for Trade in Services (CIFTIS). REUTERS / Tingshu Wang

The extent of inoculation under the emergency program, which China initiated in July, but has released some details about it, indicates how active the use of experimental vaccines to protect workers needed against potential COVID-19 resurgence Being used by, even testing. In the process.

The program is for specific groups, including medical staff and people working in food markets and in the transport and service sectors.

Synovac, whose Coronavac is in Phase 3 clinical trials and included in the emergency plan, offered the candidate the vaccine on a voluntary basis to about 2,000 to 3,000 employees and their families, CEO Yin Weidong told Reuters.

“As a vaccine developer and manufacturer, a new outbreak could directly affect our vaccine production,” Yin said at an international trade fair in Beijing, explaining why his company was involved in the emergency program had gone.

Data collected from the program may present evidence of vaccine safety, but such data, which is not part of the registered clinical trial protocol, will not be used as the main material, given that the regulatory review Let’s decide whether to approve the vaccine for commercial use, Yin said.

He said that those who wanted to vaccinate, including his wife and parents, were told of the possible side effects before taking the shot, and that the vaccine was only to complete early and mid-stage trials.

Yin, who also took the shot, said doctors asked about her health conditions before vaccination, and that the incidence of adverse reactions among vaccinators has been “very low”.

Side effects after taking Coronavac include fatigue, fever, and pain, mostly with mild symptoms, according to the results of a mid-stage trial sponsored by Synovac, involving 600 participants and published before peer review last month . bit.ly/2GwIz9b

With no vaccine finalized, large-scale testing is effective and safe enough to prove that more than 870,000 deaths have occurred enough to protect people from the virus.

(This story corrects the typo in the 9th paragraph.)

Reporting by Roxanne Liu and Tony Munro; Editing by Miang Kim and William Mallard

Our standard:Thomson Reuters Trust Theory.

Leave a Reply

Your email address will not be published.